Dedicated to the discovery and development
of therapeutics for inflammatory diseases
Resolvyx is defining a new therapeutic paradigm for controlling inflammation by activating endogenous resolution pathways—the body’s own “off-switch” for inflammation.
Resolvins are highly effective small molecules with outstanding risk-benefit profiles, relevant to a wide range of acute and chronic diseases. They carry a number of benefits over classical therapeutics that inhibit inflammation, including:
- Dampen entire networks of multiple pro-inflammatory mediators
- Effect cells of both the innate and the adaptive arms of the immune system
- Control inflammation without leading to immunosuppression
- Demonstrate enhanced safety profile by mimicking endogenous control mechanisms